Syndax Pharmaceuticals

Advances In Precision Medicine Will Transform Oncology Markets

AnalystHighTarget

Not Invested

Community Contributor

Published

06 Aug 25

AnalystHighTarget's Fair Value

US$56.00

70.7% undervalued

10 Sep

US$16.40

-10.2%

5.4%

-10.2%

5.4%

You can edit this narrative until Aug 6 9:28 PM. Then, changes will post as Updates.

Author's Valuation

US$5670.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$56

70.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

40.04%

Biotech revenue growth rate

8.35%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.20%

Calculation

US$128.56m

Earnings '28

47.07x

PE Ratio '28

US$6.05b

Market Cap '28

US$6.05b

Market Cap '28

88.54m

No. shares '28

US$68.35

Share Price '28

US$68.35 Share Price '28

Discounted to 2025 @ 7.08% p.a.

US$55.66

Fair Value '25